Joseph Dillon, MD
Endocrinology, Diabetes & Metabolism · Iowa City, IANPI 1710960026
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,842 of the $1,902 with a category attached, or 96.8%. Every reported general payment came from a single manufacturer, Progenics Pharmaceuticals, Inc..
Across 2 payments — averaging $951.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Progenics Pharmaceuticals, Inc.$2K
Across 4 payments — averaging $59,714 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Progenics Pharmaceuticals, Inc.$239K
What the payments were for
- Consulting fees$1,84297%
- Food & beverage$603%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Progenics Pharmaceuticals, Inc. | 2 | $1,902 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AZEDRA$1,842
How this compares
$1,902 in reported general payments places this provider in the 75th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
See all endocrinology, diabetes & metabolism providers in Iowa →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Octreotide Acetate | 20 | $13,617 |
| Levothyroxine Sodium | 21 | $199 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Iowa City
- Ayotunde DokunIowa City$31K
- Marcelo CorreiaIowa City$10K
- Thomas OdorisioIowa City$7K
- Amie OgunsakinIowa City$2K
- Adeyinka TaiwoIowa City$923
- Rana TaljIowa City$566
- Kathleen RobinsonIowa City$298
- Helen Prathiba GnanapragasamIowa City$281
- Brian OneillIowa City$164
- Amr WahbaIowa City$164
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.